Todos Med Ltd (TOMDF)

[JoeForkeyBolo]

CEO Twitter posts Oct 4

Jay70272671 tweet:

@G_Commish
we just want answers u seem to have the covid solution nailed perfectly but as far as this public company goes its currently a train wreck this stock should be 10x the current price

GC replying to Jay70272671:

A few more milestones are forthcoming and the picture will be clear. We are looking at best options to ensure common stock retains and increases in value as we execute. We are well into implementation with several labs and expect the cash to begin to turn in October.

We are keeping our legacy clients from the initial sales model of just selling machines and reagents without the integrated solution, and we expect several of them will transition into our fully scalable solution with AID that will allow them to get to 10,000 PCR tests per day very rapidly. The antigen tests are causing significant increase in need for confirmatory PCR testing and authorities have realized PCR is the only way for skilled nursing. As such numbers of tests will go up regardless of if positivity goes up. We expect positivity to go up as the weather gets colder and restrictions relax across the country. This is an important step in beginning to manage the pandemic because it will show us if we can ‘live with the virus’. Personally I think all focus should be on remedies and mitigation efforts and figure out who is infected and make the patient become negative as quickly as possible. Time to negative test is critical and we think our mobile lab strategy combined with our dietary supplement strategy could be game changing for two key drivers of the pandemic.

And with regards to AID PCR capacity - we can now get clients up to 50,000 tests per day. Given that the Abbott antigen tests are responsible for the White House event, I suspect many realize PCR is the way to go until our 3C tests hits the market. Antigen biology is flawed and the only way to use effectively is with serial tests. This needs to be stressed and the performance needs to be monitored closely. Low LOD PCR is key to pickup very early disease. Need to address sample collection broadly. Naso not viable. Oropharyngeal best option for now.

A few more milestones are forthcoming and the picture will be clear. We are looking at best options to ensure common stock retains and increases in value as we execute. We are well into implementation with several labs and expect the cash to begin to turn in October. 1/

— Gerald Commissiong (@G_Commish) October 3, 2020